Press Releases

Date	Title
Oct 9, 2024	Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
Oct 7, 2024	Illumina to Announce Third Quarter 2024 Financial Results on Monday, November 4, 2024
Oct 3, 2024	Charles Dadswell to step down as General Counsel, Illumina initiates search for successor
Sep 3, 2024	European Court of Justice rules in favor of Illumina in jurisdictional appeal
Aug 27, 2024	FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
Aug 13, 2024	Illumina announces strategy to accelerate value creation
Aug 6, 2024	Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024
Aug 5, 2024	Illumina launches new oncology menu for NovaSeq X Series customers
Jul 18, 2024	Illumina to Present Upcoming Strategy Update
Jul 11, 2024	Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Jul 9, 2024	Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base
Jun 24, 2024	Illumina completes the divestiture of GRAIL
Jun 11, 2024	Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations
Jun 4, 2024	Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost
Jun 3, 2024	Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
Jun 3, 2024	Illumina appoints Everett Cunningham Chief Commercial Officer
May 29, 2024	Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
May 28, 2024	Illumina releases 2023 Corporate Social Responsibility Report
May 20, 2024	Anna Richo joins Illumina's Board of Directors
May 15, 2024	Illumina To Webcast Upcoming Investor Conference
May 6, 2024	Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
May 3, 2024	Illumina To Webcast Upcoming Investor Conference
May 2, 2024	Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
Apr 12, 2024	Illumina's planned divestment of GRAIL approved by the European Commission
Apr 9, 2024	Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Apr 4, 2024	Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
Feb 8, 2024	Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
Jan 9, 2024	Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
Jan 5, 2024	Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
Jan 4, 2024	Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
Jan 4, 2024	The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk

Press releases

Stay on top of breaking news from Illumina

For every lab, everywhere

NextSeq 1000 and NextSeq 2000 Reagents

Sequencing platform comparison

DRAGEN v4.3 now available on-premises and on-cloud

Illumina Proactive Instrument Performance Service

Do more, faster than ever

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

Next-generation sequencing for beginners

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

This is the Genome Era

Illumina DRAGEN secondary analysis v4.3

Illumina DRAGEN secondary analysis v4.3

Illumina DRAGEN secondary analysis v4.3

Illumina DRAGEN secondary analysis v4.3

Illumina DRAGEN secondary analysis v4.3

Illumina DRAGEN secondary analysis v4.3

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

For every lab, everywhere

Press Releases

Press releases

Stay on top of breaking news from Illumina